2,187
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Direct and indirect economic burden of lung cancer in Denmark a nationwide study

ORCID Icon, , , , ORCID Icon, & show all
Article: 1951963 | Received 06 May 2021, Accepted 01 Jul 2021, Published online: 29 Jul 2021

References

  • GLOBOCAN https://gco.iarc.fr/
  • NORDCAN https://www-dep.iarc.fr/nordcan/dk/frame.asp
  • Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-medicare data. Med Care. 2002;40(8suppl):IV-104-IV-117.
  • ERS. The economic burden of lung disease. In: Gibson GJ, Loddenkemper R, Sibille Y, et al., editors. European lung white book. UK: European Respiratory Society; 2013. p. 16–8.
  • Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol. 1998. Dec;16(12):3900–3912. Review.
  • Olsen J, Brønnum-Hansen H, Gissler M, et al. High-throughput epidemiology: combining existing data from the Nordic countries in health-related collaborative research. Scand J Public Health. 2010;38(7):777–779.
  • Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European union: a population-based cost analysis. Lancet Oncol. 2013 Nov;14(12):1165–1174.
  • Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
  • Pedersen CB. The Danish Civil Registration System. Scand J Pulic Health. 2011;32:183–190.
  • Løkke A, Hilberg O, Tønnesen P, et al. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open. 2014 Jan 6;4(1):e004069.
  • Rittig AH, Hilberg O, Ibsen R, et al. Incidence, comorbidity and survival rate of hypersensitivity pneumonitis: a national population-based study. ERJ Open Res. 2019 Oct 21;5(4):00259–2018.
  • Gade Sikjær M, Hilberg O, Ibsen R, et al. Direct and indirect economic and health consequences related to sarcoidosis in Denmark: a national register-based study. Respir Med. 2019 Jun;152:7–13.
  • Gouliaev A, Hilberg O, Christensen NL, et al. Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis. Eur Clin Respir J. 2020;8(1):1861579.
  • Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017 May;143(5):783–791.
  • Andreas S, Chouaid C, Danson S, et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the UK: a retrospective observational study (LuCaBIS). Lung Cancer. 2018Oct;124:298–309.
  • Zhang X, Liu S, Liu Y, et al. Economic burden for lung cancer survivors in Urban China. Int J Environ Res Public Health. 2017 Mar 15;14(3):E308.
  • Kruse M, Hostenkamp G De samfundsøkonomiske omkostninger ved kræft, sep. 2016, COHERE. 258 s
  • Goldsbury DE, Weber MF, Yap S, et al. Health services costs for lung cancer care in Australia: estimates from the 45 and up study. PLoS ONE. 2020;15(8):e0238018.
  • Iachina M, Jakobsen E, Møller H, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung. 2015 Apr;193(2):291–297.
  • Islam KM, Jiang X, Anggondowati T, et al. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1079–1085.
  • Zarogoulidou V, Panagopoulou E, Papakosta D, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek university pulmonary department. J Thorac Dis. 2015 Feb;7(Suppl 1):S12–9.
  • Darbà J, Marsà A. The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period. BMC Cancer. 2019;19(1):992.
  • Falchs E, Eriksen L, Koch MB et al. Sygdomsbyrden i Danmark. Oct 2015. Sundheddstyrrelsen/Danish Health Authoroty. https://www.sst.dk/da/sygdom-og-behandling/~/media/00C6825B11BD46F9B064536C6E7DFBA0.ashx
  • Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care. 2008 Sep;14(9):565–571.
  • Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer. 2019 Mar 8;19(1):214.
  • Jakobsen E, Green A, Oesterlind K, et al. Nationwide quality improvement in lung cancer care: the role of the Danish Lung Cancer Group and Registry. J Thorac Oncol. 2013;8(10):1238–1247.
  • Jakobsen E, Rasmussen TR. The Danish lung cancer registry. Clin Epidemiol. 2016;8:537–541.
  • Van der Heyden JH, Schaap MM, Kunst AE, et al. Socioeconomic inequalities in lung cancer mortality in 16 European populations. Lung Cancer. 2009 Mar;63(3):322–330.
  • Fløe A, Hilberg O, Weise C, et al. The economic burden of tuberculosis in Denmark 1998-2010. Cost analysis in patient and their spouses. Int J Infect Dic. 2015 Mar;32:183–190.
  • Postmus PE, Kerr KM, Oudkerk M, et al. ESMO guidelines committee. Ann Oncol. 2017;28(suppl_4):iv1–iv21.